A month has gone by since the last earnings report for Pfizer (PFE). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...
Third-quarter 2025 Cost of Sales(3) as a percentage of revenues decreased by 4.7 percentage points compared to the prior-year quarter, primarily driven by (i) a favorable revision of our estimate of ...
Hosted on MSN
Pfizer, Astellas report positive phase 3 trial results for PADCEV combination in bladder cancer treatment
Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, Astellas Pharma and Pfizer Inc. (NYSE:PFE) announced positive topline results ...
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results